NCT06162546 ARREST-NEPHROSIS - Austrian Resistant Nephrotic Syndrome Treatment Response Registry and Biobank
| NCT ID | NCT06162546 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Christoph Aufricht |
| Condition | Focal Segmental Glomerulosclerosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2023-01-01 |
| Primary Completion | 2033-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2023-01-01 with a primary completion date of 2033-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Nephrotic syndrome is the clinical phenotype of a heterogeneous group of glomerular diseases that may present with varying degrees of urinary protein loss (proteinuria), dysproteinemia in the blood, fluid retention and impaired renal function. The AustRian RESistanT NEPHROtic Syndrome Treatment Response RegIStry and Biobank (ARREST-NEPHROSIS) sets out to achieve the following goals, as typical categories of rare disease registries 1. Obtaining real world data on practice patterns and outcomes 2. Networking between affected patients, families, and clinicians. 3. Establish a patient base for facilitated recruitment in studies of drugs, medical devices, and products 4. Development of a Biobank to enable research of potential biomarkers and therapy or disease courses
Eligibility Criteria
Inclusion Criteria: * Resistant to standard Immunosuppressive agents (if clinically indicated, e.g. primary/non-genetic forms) * Persistent urinary protein-to-creatinine (UP/C) ratio \>1.0 g/g * eGFR \> 30 ml/min per 1.73 m2 * biopsy or a disease-causing genetic mutation associated with nephrotic syndrome Exclusion Criteria: * Inability or unwillingness to comply with repeated assessments * Objections against participation at discretion of the investigator * Secondary * Patients with steroid-dependence/frequently relapsing disease (but achievement of complete remission)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06162546 clinical trial?
This trial is open to participants of all sexes, up to 75 Years, studying Focal Segmental Glomerulosclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06162546 currently recruiting?
Yes, NCT06162546 is actively recruiting participants. Contact the research team at christoph.aufricht@meduniwien.ac.at for enrollment information.
Where is the NCT06162546 trial being conducted?
This trial is being conducted at Vienna, Austria.
Who is sponsoring the NCT06162546 clinical trial?
NCT06162546 is sponsored by Christoph Aufricht. The trial plans to enroll 100 participants.